acriflavine and AIDS-Related-Complex

acriflavine has been researched along with AIDS-Related-Complex* in 2 studies

Other Studies

2 other study(ies) available for acriflavine and AIDS-Related-Complex

Article	Year
The failure of HAART to cure the HIV-1/AIDS complex. Suggestions to add integrase inhibitors as complementary virostatics, and to replace their continuous long combination applications by short sequences differing by drug rotations. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2001, Volume: 55, Issue:6 While the intensive virostatic combinations applied according to the conventional models (such as HAART), based only on the attacks of two HIV-1 targets, retrotranscriptase and protease, and applied in a long and continuous fashion, a) are notably toxic, b) do not correct completely the abnormal immunologic parameters, and c) are followed by particularly severe and poorly sensitive relapses in case of discontinuation, we propose to the 'AIDS treatment headquarters' to include in their failing strategy the two original features which we have included in the treatment of a cohort of a dozen patients, treatment applied at all but one AIDS stage. We attack one more HIV-1 target than the conventional protocols do, by adding inhibitors of integrase; we apply the combinations of virostatics, comprising inhibitors of the three targets, in short sequences (of 3 weeks), between which the analogues are changed inside each series. The first patient of the cohort started his treatment 8.5 years ago, and the entries of the others into it have been at random and not randomized. All patients are alive today and in excellent condition. Topics: Acquired Immunodeficiency Syndrome; Acriflavine; AIDS-Related Complex; Animals; Anti-Infective Agents, Local; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Resistance, Viral; Ellipticines; HIV Integrase Inhibitors; HIV-1; Humans; Immunosuppressive Agents	2001
In vivo eradication of Friend virus as an experimental HIV-model, by combination of zidovudine, acriflavine and an ellipticine analogue. Possible application to the treatment of human pre-AIDS? Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1994, Volume: 48, Issue:2 Simultaneous administration of zidovudine, acriflavine and celliptium to Friend virus-injected mice eradicates the virus, as evidenced by the impossibility of the treated-mouse serum, when injected to virgin recipients, to induce spleen foci formation. An adapted preliminary protocol given to patients in whose p 24 antigen was present in the blood, lead to a considerable reduction of that marker. The cures lasted 3 weeks, and were repeated after 3-week intervals. Since p 24 antigen returns to pre-treatment levels at the end of the interval, research should concentrate on the maintenance of the effect during the interval. Topics: Acquired Immunodeficiency Syndrome; Acriflavine; AIDS-Related Complex; Animals; Drug Therapy, Combination; Ellipticines; Friend murine leukemia virus; HIV Infections; Humans; Male; Mice; Mice, Inbred DBA; Zidovudine	1994

Article

Year

The failure of HAART to cure the HIV-1/AIDS complex. Suggestions to add integrase inhibitors as complementary virostatics, and to replace their continuous long combination applications by short sequences differing by drug rotations.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2001, Volume: 55, Issue:6

While the intensive virostatic combinations applied according to the conventional models (such as HAART), based only on the attacks of two HIV-1 targets, retrotranscriptase and protease, and applied in a long and continuous fashion, a) are notably toxic, b) do not correct completely the abnormal immunologic parameters, and c) are followed by particularly severe and poorly sensitive relapses in case of discontinuation, we propose to the 'AIDS treatment headquarters' to include in their failing strategy the two original features which we have included in the treatment of a cohort of a dozen patients, treatment applied at all but one AIDS stage. We attack one more HIV-1 target than the conventional protocols do, by adding inhibitors of integrase; we apply the combinations of virostatics, comprising inhibitors of the three targets, in short sequences (of 3 weeks), between which the analogues are changed inside each series. The first patient of the cohort started his treatment 8.5 years ago, and the entries of the others into it have been at random and not randomized. All patients are alive today and in excellent condition.

Topics: Acquired Immunodeficiency Syndrome; Acriflavine; AIDS-Related Complex; Animals; Anti-Infective Agents, Local; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Resistance, Viral; Ellipticines; HIV Integrase Inhibitors; HIV-1; Humans; Immunosuppressive Agents

2001

In vivo eradication of Friend virus as an experimental HIV-model, by combination of zidovudine, acriflavine and an ellipticine analogue. Possible application to the treatment of human pre-AIDS?

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1994, Volume: 48, Issue:2

Simultaneous administration of zidovudine, acriflavine and celliptium to Friend virus-injected mice eradicates the virus, as evidenced by the impossibility of the treated-mouse serum, when injected to virgin recipients, to induce spleen foci formation. An adapted preliminary protocol given to patients in whose p 24 antigen was present in the blood, lead to a considerable reduction of that marker. The cures lasted 3 weeks, and were repeated after 3-week intervals. Since p 24 antigen returns to pre-treatment levels at the end of the interval, research should concentrate on the maintenance of the effect during the interval.

Topics: Acquired Immunodeficiency Syndrome; Acriflavine; AIDS-Related Complex; Animals; Drug Therapy, Combination; Ellipticines; Friend murine leukemia virus; HIV Infections; Humans; Male; Mice; Mice, Inbred DBA; Zidovudine

1994